{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T05:08:24Z","timestamp":1792559304370,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T00:00:00Z","timestamp":1690588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T00:00:00Z","timestamp":1690588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010476","name":"Tata Memorial Centre","doi-asserted-by":"publisher","award":["TRAC\/1019\/900516\/001"],"award-info":[{"award-number":["TRAC\/1019\/900516\/001"]}],"id":[{"id":"10.13039\/501100010476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The emergence of resistance to the highly successful BCL2-directed therapy is a major unmet need in acute myeloid leukemia (AML), an aggressive malignancy with poor survival rates. Towards identifying therapeutic options for AML patients who progress on BCL2-directed therapy, we studied a clinical-stage CDK7 inhibitor XL102, which is being evaluated in solid tumors (NCT04726332).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>To determine the anti-proliferative effects of XL102, we performed experiments including time-resolved fluorescence resonance energy transfer, target occupancy, cell cycle and apoptosis-based assays. We also included genetically characterized primary myeloid blasts from de novo and relapsed\/refractory AML patients. For mechanistic studies, CRISPR\/Cas9 mediated knockout of CDK7 and c-Myc and immunoblotting were performed. NOD\/SCID orthotropic and subcutaneous AML xenografts were used to determine anti-leukemic effects. To assess the synergistic effects of XL102 with Venetoclax, we performed RNA sequencing and gene set enrichment analysis using Venetoclax sensitive and resistant model systems.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      XL102, a highly specific, orally bioavailable covalent inhibitor of CDK7. Inhibitory effect on CDK7 by XL102 in primary myeloid blasts (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200954) was in nanomolar range (mean\u2009=\u2009300\u00a0nM; range\u2009=\u20094.0-952\u00a0nM). XL102 treated AML cells showed a reduction in phosphorylation levels of Serine 2\/5\/7 at carboxy-terminal domain of RNA polymerase II. T-loop phosphorylation of CDK1(Thr161) and CDK2(Thr160) was inhibited by XL102 in dose-dependent manner leading to cell-cycle arrest. c-Myc downregulation and enhanced levels of p53 and p21 in XL102 treated cells were observed. Increased levels of p21 and activation of p53 by XL102 were mimicked by genetic ablation of CDK7, which supports that the observed effects of XL102 are due to CDK7 inhibition. XL102 treated AML xenografts showed remarkable reduction in hCD45\u2009+\u2009marrow cells (mean\u2009=\u20090.60%; range\u2009=\u20090.04%-3.53%) compared to vehicle control (mean\u2009=\u200938.2%; range\u2009=\u200910.1%-78%), with corresponding increase in p53, p21 and decrease in c-Myc levels. The data suggests XL102 induces apoptosis in AML cells via CDK7\/c-Myc\/p53 axis. RNA-sequencing from paired Venetoclax-sensitive and Venetoclax-resistant cells treated with XL102 showed downregulation of genes involved in proliferation and apoptosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Taken together, XL102 with Venetoclax led to synergistic effects in overcoming resistance and provided a strong rationale for clinical evaluation of XL102 as a single agent and in combination with Venetoclax.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-023-02750-w","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T22:01:43Z","timestamp":1690581703000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax"],"prefix":"10.1186","volume":"42","author":[{"given":"Tarang","family":"Gaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramulu","family":"Poddutoori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Khare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhausaheb","family":"Bagal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonal","family":"Rashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Patkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Tembhare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subramanian","family":"PG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhanlaxmi","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Dutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Platzbeckar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeep","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanta","family":"Samajdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali","family":"Ramchandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navin","family":"Khattry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed K.","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,29]]},"reference":[{"issue":"10","key":"2750_CR1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41408-020-00376-1","volume":"10","author":"N Daver","year":"2020","unstructured":"Daver N, Wei AH, Pollyea DA, Fathi AT, Vyas P, DiNardo CD. New directions for emerging therapies in acute myeloid leukemia: the next chapter. Blood Cancer J. 2020;10(10):107.","journal-title":"Blood Cancer J"},{"issue":"12","key":"2750_CR2","doi-asserted-by":"publisher","first-page":"e922","DOI":"10.1016\/S2352-3026(21)00270-2","volume":"8","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian H, Short NJ, DiNardo C, Stein EM, Daver N, Perl AE, et al. Harnessing the benefits of available targeted therapies in acute myeloid leukaemia. Lancet Haematol. 2021;8(12):e922\u201333.","journal-title":"Lancet Haematol"},{"issue":"4","key":"2750_CR3","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/bjh.15032","volume":"180","author":"S Kayser","year":"2018","unstructured":"Kayser S, Levis MJ. Advances in targeted therapy for acute myeloid leukaemia. Br J Haematol. 2018;180(4):484\u2013500.","journal-title":"Br J Haematol"},{"key":"2750_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2026","volume":"375","author":"LF Newell","year":"2021","unstructured":"Newell LF, Cook RJ. Advances in acute myeloid leukemia. BMJ. 2021;375: n2026.","journal-title":"BMJ"},{"key":"2750_CR5","first-page":"1","volume":"42","author":"GW Roloff","year":"2022","unstructured":"Roloff GW, Odenike O, Bajel A, Wei AH, Foley N, Uy GL. Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022. Am Soc Clin Oncol Educ Book. 2022;42:1\u201316.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"2750_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11(2):41.","journal-title":"Blood Cancer J"},{"key":"2750_CR7","doi-asserted-by":"crossref","unstructured":"Bogenberger J, Whatcott C, Hansen N, Delman D, Shi CX, Kim W, et al. Combined venetoclax and alvocidib in acute myeloid leukemia. Oncotarget. 2017;8(63):107206\u201310722.","DOI":"10.18632\/oncotarget.22284"},{"issue":"13","key":"2750_CR8","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1158\/0008-5472.CAN-19-0119","volume":"79","author":"S Hu","year":"2019","unstructured":"Hu S, Marineau JJ, Rajagopal N, Hamman KB, Choi YJ, Schmidt DR, et al. Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7. Cancer Res. 2019;79(13):3479\u201391.","journal-title":"Cancer Res"},{"key":"2750_CR9","doi-asserted-by":"crossref","unstructured":"Pan R, Ruvolo V, Mu H, Leverson JD, Nichols G, Reed JC, et al. Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy. Cancer Cell. 2017;32(6):748\u201360 e6.","DOI":"10.1016\/j.ccell.2017.11.003"},{"key":"2750_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.663360","volume":"11","author":"T Abudureheman","year":"2021","unstructured":"Abudureheman T, Xia J, Li MH, Zhou H, Zheng WW, Zhou N, et al. CDK7 Inhibitor THZ1 Induces the Cell Apoptosis of B-Cell Acute Lymphocytic Leukemia by Perturbing Cellular Metabolism. Front Oncol. 2021;11: 663360.","journal-title":"Front Oncol"},{"issue":"3","key":"2750_CR11","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/odi.13783","volume":"28","author":"H Ge","year":"2022","unstructured":"Ge H, Yao Y, Jiang Y, Wu X, Wang Y. Pharmacological inhibition of CDK7 by THZ1 impairs tumor growth in p53-mutated HNSCC. Oral Dis. 2022;28(3):611\u201320.","journal-title":"Oral Dis"},{"issue":"5","key":"2750_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2017.33","volume":"6","author":"SA Greenall","year":"2017","unstructured":"Greenall SA, Lim YC, Mitchell CB, Ensbey KS, Stringer BW, Wilding AL, et al. Cyclin-dependent kinase 7 is a therapeutic target in high-grade glioma. Oncogenesis. 2017;6(5): e336.","journal-title":"Oncogenesis"},{"issue":"7511","key":"2750_CR13","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nature13393","volume":"511","author":"N Kwiatkowski","year":"2014","unstructured":"Kwiatkowski N, Zhang T, Rahl PB, Abraham BJ, Reddy J, Ficarro SB, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 2014;511(7511):616\u201320.","journal-title":"Nature"},{"key":"2750_CR14","doi-asserted-by":"crossref","unstructured":"Zhang H, Christensen CL, Dries R, Oser MG, Deng J, Diskin B, et al. CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer. Cancer Cell. 2020;37(1):37\u201354 e9.","DOI":"10.1016\/j.ccell.2019.11.003"},{"issue":"9","key":"2750_CR15","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1158\/1535-7163.MCT-17-0078","volume":"16","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Peng H, Wang X, Yin X, Ma P, Jing Y, et al. Preclinical Efficacy and Molecular Mechanism of Targeting CDK7-Dependent Transcriptional Addiction in Ovarian Cancer. Mol Cancer Ther. 2017;16(9):1739\u201350.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"2750_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","volume":"7","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, et al. Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct Target Ther. 2022;7(1):51.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"2750_CR17","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1159\/000516655","volume":"161","author":"J McGowan-Jordan","year":"2021","unstructured":"McGowan-Jordan J, Hastings R, Moore S. Re: International System for Human Cytogenetic or Cytogenomic Nomenclature (ISCN): Some Thoughts, by T. Liehr Cytogenet Genome Res. 2021;161(5):225\u20136.","journal-title":"Liehr Cytogenet Genome Res"},{"issue":"5","key":"2750_CR18","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1038\/s41375-021-01131-6","volume":"35","author":"N Patkar","year":"2021","unstructured":"Patkar N, Kakirde C, Shaikh AF, Salve R, Bhanshe P, Chatterjee G, et al. Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML). Leukemia. 2021;35(5):1392\u2013404.","journal-title":"Leukemia"},{"issue":"2","key":"2750_CR19","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440\u20136.","journal-title":"Cancer Res"},{"issue":"8","key":"2750_CR20","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nmeth.3047","volume":"11","author":"NE Sanjana","year":"2014","unstructured":"Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods. 2014;11(8):783\u20134.","journal-title":"Nat Methods"},{"issue":"19","key":"2750_CR21","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1128\/MCB.00595-14","volume":"34","author":"TW Kelso","year":"2014","unstructured":"Kelso TW, Baumgart K, Eickhoff J, Albert T, Antrecht C, Lemcke S, et al. Cyclin-dependent kinase 7 controls mRNA synthesis by affecting stability of preinitiation complexes, leading to altered gene expression, cell cycle progression, and survival of tumor cells. Mol Cell Biol. 2014;34(19):3675\u201388.","journal-title":"Mol Cell Biol"},{"issue":"21\u201322","key":"2750_CR22","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1101\/gad.341545.120","volume":"34","author":"JK Rimel","year":"2020","unstructured":"Rimel JK, Poss ZC, Erickson B, Maas ZL, Ebmeier CC, Johnson JL, et al. Selective inhibition of CDK7 reveals high-confidence targets and new models for TFIIH function in transcription. Genes Dev. 2020;34(21\u201322):1452\u201373.","journal-title":"Genes Dev"},{"key":"2750_CR23","doi-asserted-by":"crossref","unstructured":"Sampathi S, Acharya P, Zhao Y, Wang J, Stengel KR, Liu Q, et al. The CDK7 inhibitor THZ1 alters RNA polymerase dynamics at the 5\u2019 and 3\u2019 ends of genes. Nucleic Acids Res. 2019;47(8):3921\u201336.","DOI":"10.1093\/nar\/gkz127"},{"issue":"5","key":"2750_CR24","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.cell.2014.10.024","volume":"159","author":"E Chipumuro","year":"2014","unstructured":"Chipumuro E, Marco E, Christensen CL, Kwiatkowski N, Zhang T, Hatheway CM, et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell. 2014;159(5):1126\u201339.","journal-title":"Cell"},{"issue":"1","key":"2750_CR25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/10428194.2018.1464158","volume":"60","author":"M Ohanian","year":"2019","unstructured":"Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, et al. MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma. 2019;60(1):37\u201348.","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2750_CR26","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1038\/emboj.2012.94","volume":"31","author":"M Ganuza","year":"2012","unstructured":"Ganuza M, Saiz-Ladera C, Canamero M, Gomez G, Schneider R, Blasco MA, et al. Genetic inactivation of Cdk7 leads to cell cycle arrest and induces premature aging due to adult stem cell exhaustion. EMBO J. 2012;31(11):2498\u2013510.","journal-title":"EMBO J"},{"issue":"1","key":"2750_CR27","doi-asserted-by":"publisher","first-page":"5444","DOI":"10.1038\/s41467-019-13334-8","volume":"10","author":"C Ghezzi","year":"2019","unstructured":"Ghezzi C, Wong A, Chen BY, Ribalet B, Damoiseaux R, Clark PM. A high-throughput screen identifies that CDK7 activates glucose consumption in lung cancer cells. Nat Commun. 2019;10(1):5444.","journal-title":"Nat Commun"},{"key":"2750_CR28","doi-asserted-by":"crossref","unstructured":"Zeng M, Kwiatkowski NP, Zhang T, Nabet B, Xu M, Liang Y, et al. Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12\/13. Elife. 2018;7:1\u201320.","DOI":"10.7554\/eLife.39030"},{"issue":"12","key":"2750_CR29","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","volume":"8","author":"HE Ramsey","year":"2018","unstructured":"Ramsey HE, Fischer MA, Lee T, Gorska AE, Arrate MP, Fuller L, et al. A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia. Cancer Discov. 2018;8(12):1566\u201381.","journal-title":"Cancer Discov"},{"issue":"13","key":"2750_CR30","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1182\/blood.2020006785","volume":"138","author":"AW Roberts","year":"2021","unstructured":"Roberts AW, Wei AH, Huang DCS. BCL2 and MCL1 inhibitors for hematologic malignancies. Blood. 2021;138(13):1120\u201336.","journal-title":"Blood"},{"issue":"12","key":"2750_CR31","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H Dohner","year":"2015","unstructured":"Dohner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015;373(12):1136\u201352.","journal-title":"N Engl J Med"},{"key":"2750_CR32","doi-asserted-by":"crossref","unstructured":"Roloff GW, Odenike O, Bajel A, Wei AH, Foley N, Uy GL. Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022. Am Soc Clin Oncol Educ Book. 2022;42:1\u201316.","DOI":"10.1200\/EDBK_349605"},{"issue":"6","key":"2750_CR33","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.ccell.2014.11.012","volume":"26","author":"A Augert","year":"2014","unstructured":"Augert A, MacPherson D. Treating transcriptional addiction in small cell lung cancer. Cancer Cell. 2014;26(6):783\u20134.","journal-title":"Cancer Cell"},{"key":"2750_CR34","doi-asserted-by":"crossref","unstructured":"Park SY, Kim KY, Jun DY, Hwang SK, Kim YH. G(1) Cell Cycle Arrest and Extrinsic Apoptotic Mechanisms Underlying the Anti-Leukemic Activity of CDK7 Inhibitor BS-181. Cancers (Basel). 2020;12(12):3845.","DOI":"10.3390\/cancers12123845"},{"issue":"6","key":"2750_CR35","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/1535-7163.MCT-16-0847","volume":"17","author":"H Patel","year":"2018","unstructured":"Patel H, Periyasamy M, Sava GP, Bondke A, Slafer BW, Kroll SHB, et al. ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment. Mol Cancer Ther. 2018;17(6):1156\u201366.","journal-title":"Mol Cancer Ther"},{"key":"2750_CR36","doi-asserted-by":"crossref","unstructured":"Olson CM, Liang Y, Leggett A, Park WD, Li L, Mills CE, et al. Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype. Cell Chem Biol. 2019;26(6):792\u2013803 e10.","DOI":"10.1016\/j.chembiol.2019.02.012"},{"key":"2750_CR37","doi-asserted-by":"crossref","unstructured":"Minzel W, Venkatachalam A, Fink A, Hung E, Brachya G, Burstain I, et al. Small Molecules Co-targeting CKIalpha and the Transcriptional Kinases CDK7\/9 Control AML in Preclinical Models. Cell. 2018;175(1):171\u201385 e25.","DOI":"10.1016\/j.cell.2018.07.045"},{"issue":"12","key":"2750_CR38","doi-asserted-by":"publisher","first-page":"7220","DOI":"10.1128\/MCB.17.12.7220","volume":"17","author":"LJ Ko","year":"1997","unstructured":"Ko LJ, Shieh SY, Chen X, Jayaraman L, Tamai K, Taya Y, et al. p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner. Mol Cell Biol. 1997;17(12):7220\u20139.","journal-title":"Mol Cell Biol"},{"issue":"9","key":"2750_CR39","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.exphem.2016.05.014","volume":"44","author":"K Kojima","year":"2016","unstructured":"Kojima K, Ishizawa J, Andreeff M. Pharmacological activation of wild-type p53 in the therapy of leukemia. Exp Hematol. 2016;44(9):791\u20138.","journal-title":"Exp Hematol"},{"key":"2750_CR40","doi-asserted-by":"crossref","unstructured":"Baluapuri A, Hofstetter J, Dudvarski Stankovic N, Endres T, Bhandare P, Vos SM, et al. MYC Recruits SPT5 to RNA Polymerase II to Promote Processive Transcription Elongation. Mol Cell. 2019;74(4):674\u201387 e11.","DOI":"10.1016\/j.molcel.2019.02.031"},{"issue":"6","key":"2750_CR41","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1128\/MCB.01828-06","volume":"27","author":"VH Cowling","year":"2007","unstructured":"Cowling VH, Cole MD. The Myc transactivation domain promotes global phosphorylation of the RNA polymerase II carboxy-terminal domain independently of direct DNA binding. Mol Cell Biol. 2007;27(6):2059\u201373.","journal-title":"Mol Cell Biol"},{"issue":"34","key":"2750_CR42","doi-asserted-by":"publisher","first-page":"31263","DOI":"10.1074\/jbc.M202528200","volume":"277","author":"AJ Obaya","year":"2002","unstructured":"Obaya AJ, Kotenko I, Cole MD, Sedivy JM. The proto-oncogene c-myc acts through the cyclin-dependent kinase (Cdk) inhibitor p27(Kip1) to facilitate the activation of Cdk4\/6 and early G(1) phase progression. J Biol Chem. 2002;277(34):31263\u20139.","journal-title":"J Biol Chem"},{"issue":"14","key":"2750_CR43","doi-asserted-by":"publisher","first-page":"10913","DOI":"10.1074\/jbc.M010975200","volume":"276","author":"Y Ramanathan","year":"2001","unstructured":"Ramanathan Y, Rajpara SM, Reza SM, Lees E, Shuman S, Mathews MB, et al. Three RNA polymerase II carboxyl-terminal domain kinases display distinct substrate preferences. J Biol Chem. 2001;276(14):10913\u201320.","journal-title":"J Biol Chem"},{"issue":"7626","key":"2750_CR44","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature19830","volume":"538","author":"A Kotschy","year":"2016","unstructured":"Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016;538(7626):477\u201382.","journal-title":"Nature"},{"issue":"1","key":"2750_CR45","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/1873-3468.12497","volume":"591","author":"T Lee","year":"2017","unstructured":"Lee T, Bian Z, Zhao B, Hogdal LJ, Sensintaffar JL, Goodwin CM, et al. Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors. FEBS Lett. 2017;591(1):240\u201351.","journal-title":"FEBS Lett"},{"key":"2750_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.561","volume":"6","author":"JD Leverson","year":"2015","unstructured":"Leverson JD, Zhang H, Chen J, Tahir SK, Phillips DC, Xue J, et al. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis. 2015;6: e1590.","journal-title":"Cell Death Dis"}],"updated-by":[{"DOI":"10.1186\/s13046-026-03824-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000}}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-023-02750-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-023-02750-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-023-02750-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:32:38Z","timestamp":1789709558000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-023-02750-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,29]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2750"],"URL":"https:\/\/doi.org\/10.1186\/s13046-023-02750-w","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,29]]},"assertion":[{"value":"5 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: the authors found out errors in Figure 2F.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13046-026-03824-1","URL":"https:\/\/doi.org\/10.1186\/s13046-026-03824-1","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Institutional Ethics Committee:\n                      All patients and donors in cluded in this study provided written informed consent following the Declaration of Helsinki, and the ethics Committee of Tata Memorial Centre, Mumbai (TMC-IEC III) DCGI registration number:IECIII: ECR\/149\/Inst\/MH\/2013 approved the study (approval reference number: 900516\/2018).\n                      Institute Animal Ethics Committtee\n                      : All NOD\/SCID mice experiments were conducted in accordance with guidelines approved by animal ethics committee of Tata Memorial Centre, Mumbai (study reference approval number IAEC\/13\/2018).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have read the manuscript and provided their consent for the submission.","order":2,"name":"Ethics","label":"Consent for publications","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"XL102 was developed by Aurigene Oncology Limited, Bangalore, India which had entered in license agreement with Exelixis CA, USA. The work described in this manuscript was performed in the academic Hasan Lab at the non-profit Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) at Tata Memorial Centre with financial support from Department of Atomic Energy Government of India. The authors declare no competing financial interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"186"}}